[Expression of T-lymphocytes and cytokines in the decidua of mifepristone with misoprostol for terminating early pregnancy].
OBJECTIVE
To investigate the expression of T-lymphocyte subsets (CD3+, CD4+, CD8+), natural killer cells (NK cells, CD56+, CD16+), tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) in mifepristone and misoprostod treated ducidua for terminating human early pregnancy.


METHODS
Thirty eight women who volunteered to terminate their pregnancy were divided into 3 groups: mifepristone group (group I, n = 13), mifepristone with misoprostol group (group II, n = 12) and control group (group Il, n = 13), The expression of T-lymphocyte subsets, NK cells, TNF-alpha and TGF-beta were assessed by flow cytometry.


RESULTS
The expression of CD4+ were (30.91 +/- 2.57)% and (31.58 +/- 3.28)% in group I and II respectively. Which were significantly higher than that in group III (25.64 +/- 2.36)% (P < 0.05, P < 0.01). CD56+ were (22.40 +/- 2.77)% and (26.88 +/- 3.79)% in group I and II, which were significantly higher than that in group III (18.58 +/- 4.04)% (P < 0.05, P < 0.01), CD16+ were (8.98 +/- 2.18)% and (10.84 +/- 2.51)% in group I and II, which were significantly higher than that in group III (6.34 +/- 2.01)% (P < 0.01, P < 0.001). The expression of TNF-alpha in group I and II were higher than that of group III, TGF-beta in group I and II were lower than that of group III, but there was no significant difference (P > 0.05). The expression of CD3+, CD8+, CD4+/ CD8+ ratio were not significant difference among the three groups (P > 0.05).


CONCLUSIONS
Mifepristone with misoprostol for terminating early pnegnancy might be affect the expression of lymphocyte and cytokines and induce the disorder of decidual micro-environment which might be the reason of medical abortion.
Lu
S
S
Department of Obstetrics and Gynecology, Second Hospital, Hebei Medical University, Shijiazhuang 050000, China.
Wu
R
R
Wang
Z
Z
D000019:Abortifacient Agents / Q000494:pharmacology*; D000028:Abortion, Induced / Q000379:methods*; D016022:Case-Control Studies; D016207:Cytokines / Q000378:metabolism*; D003656:Decidua / Q000187:drug effects* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007694:Killer Cells, Natural / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism*; D008233:Lymphotoxin-alpha / Q000378:metabolism; D015735:Mifepristone / Q000494:pharmacology*; D016595:Misoprostol / Q000494:pharmacology*; D011247:Pregnancy; D016176:T-Lymphocyte Subsets / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000019:Abortifacient Agents; D016207:Cytokines; D008233:Lymphotoxin-alpha; D014409:Tumor Necrosis Factor-alpha; D016595:Misoprostol; D015735:Mifepristone